Metformin for obesity in children and adolescents: a systematic review.
Metformin for obesity in children and adolescents: a systematic review.
复制标题
DOI：
10.2337/dc09-0258
复制
发表时间：
2009-09
期刊：
影响因子：
16.2
通讯作者：
Viner RM
中科院分区：
文献类型：
--
作者：
Park MH;Kinra S;Ward KJ;White B;Viner RM
目的：总结二甲双胍在降低肥胖儿童和青少年非糖尿病患者体重指数和心脏代谢风险方面的疗效。我们对随机对照试验(RCT)进行了系统回顾和荟萃分析。纳入≥持续6个月、年龄≤19岁、无糖尿病的肥胖者的随机双盲随机对照试验。我们感兴趣的主要结果包括体重指数的变化和胰岛素敏感性的测量。5项试验符合纳入标准(n=320人)。与安慰剂相比，二甲双胍使BMI降低1.42 kg/m2(95%可信区间0.83~2.02)，稳态模型胰岛素抵抗评估(HOMA-IR)评分降低2.01(95%可信区间0.75~3.26)。在短期内，二甲双胍在降低高胰岛素血症肥胖儿童和青少年的体重指数和胰岛素抵抗方面似乎是适度有效的。需要在不同人群中进行更大规模、更长期的研究，以确定其在治疗超重儿童中的作用。
To summarize the efficacy of metformin in reducing BMI and cardiometabolic risk in obese children and adolescents without diabetes. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Double-blind RCTs of ≥6 months duration in obese subjects age ≤19 years without diabetes were included. Our primary outcomes of interest include changes in BMI and measures of insulin sensitivity. Five trials met inclusion criteria (n = 320 individuals). Compared with placebo, metformin reduced BMI by 1.42 kg/m2 (95% CI 0.83–2.02) and homeostasis model assessment insulin of resistance (HOMA-IR) score by 2.01 (95% CI 0.75–3.26). Metformin appears to be moderately efficacious in reducing BMI and insulin resistance in hyperinsulinemic obese children and adolescents in the short term. Larger, longer-term studies in different populations are needed to establish its role in the treatment of overweight children.
登录
查看更多内容
影响因子：
158.5
作者：
Knowler, WC;Barrett-Connor, E;Nathan, DM
通讯作者：
Nathan, DM
影响因子：
5.8
作者：
Srinivasan, Shubha;Ambler, Geoffrey R.;Cowell, Christopher T.
通讯作者：
Cowell, Christopher T.
影响因子：
5.1
作者：
Love-Osborne, Kathy;Sheeder, Jeanelle;Zeitler, Phil
通讯作者：
Zeitler, Phil
影响因子：
16.2
作者：
Lee, Joyce M.;Okumura, Megumi J.;Gurney, James G.
通讯作者：
Gurney, James G.
影响因子：
8
作者：
Freemark, M;Bursey, D
通讯作者：
Bursey, D